Alliance to advocate for specific funding into ApoE4 -related research Alzheimer’s disease is the most common cause of dementia, a group of cognitive symptoms that include memory loss, confusion, and ...

Data from Study 201 demonstrated that stopping Leqembi treatment led to a reaccumulation of amyloid-beta in the brain and reversal of cognitive benefits. The now-approved regimen means patients who ...

I recently visited Washington, D.C., and it was cold — perhaps not by the standards of northern states, but bitter compared with my home in South Florida. Now, I’ve been colder in my life, but the ...

The company recently announced results from two Phase 3 trials testing AXS-05. One study, ACCORD-2, hit its main goal while the other, ADVANCE-2, didn’t. Axsome said it will use data from these trials ...

Blocking translation to reduce toxic protein clumps The company also plans to deliver a presentation at the 2024 Alzheimer’s Association International Conference (AAIC2024), which will take place July ...

The global Phase 2b/3 trial, called Anavex 2-73-AD-004 (NCT03790709), enrolled 509 people, ages 60-85, with mild cognitive impairments or mild dementia due to Alzheimer’s. The participants were ...

Still, existing studies estimate that Alzheimer’s is misdiagnosed at a rate of about 30-50%. While PET scans and analyses of the fluid that surrounds the brain and spinal cord increase diagnostic ...

TRANQUILITY II trial finds BXCL501 safe, effective, well tolerated Dexmedetomidine, the active agent in BXCL501, works to activate certain brain proteins, known as alpha-2a adrenergic receptors, which ...

“Results of our open-label proof-of-concept study with COYA 301 in 8 patients with Alzheimer’s showed encouraging results,” Howard Berman, PhD, Coya’s CEO, said in an emailed statement to Alzheimer’s ...

With this approval, Rexulti has now become the first and only therapy ever approved for this specific indication in the U.S. “Today marks a major milestone for patients, caregivers, and families ...

The Phase 1b portion was a one-month ascending dose phase to assess its safety, tolerability, and pharmacological properties. In the Phase 2 efficacy portion, participants were randomly assigned ...

Virtually all cases of Alzheimer’s are characterized by amyloid-beta plaques in the brain — clumps of protein that are toxic to brain cells and are thought to drive the disease. Lecanemab is designed ...